Nexel, a company specializing in organoids derived from human induced pluripotent stem cells (hiPSC), announced on the 14th that it had submitted a preliminary evaluation for KOSDAQ technology special listing to the Korea Exchange. The listing manager is NH Investment & Securities. Nexel has proven its technology by passing the newly changed and strict evaluation criteria in last year's technology evaluation.

Nexel, established in 2012, is the first bio company in Korea to commercialize its proprietary hiPSC-derived somatic cell differentiation technology. Its main businesses include hiPSC-derived functional somatic cell products, safety and efficacy evaluation services for new drugs using them, custom development and manufacturing (CMDO) of hiPSC cells, iPSC-derived organoid products, and development of new drug candidates using hiPSC-derived proteins, etc. in Japan. , China, and the United States, securing a customer base of several global pharmaceutical companies and KOLs.

Nexel is a member of HESI, an organization that develops and verifies the test methods of the ICH guidelines, and is the only company in Korea to participate in the revision study of the ICH Cardiovascular Safety Pharmacology Evaluation Guidelines (E14/S7B). In addition, the company is leading the world in obtaining ISO 17025 for cardiac safety evaluation services using hiPSC-derived cardiomyocytes, leading the standard of testing methods in the global market.

Recently, in line with alternative animal testing methods, we have successfully developed heart disease model organoids and are strengthening our capabilities to confirm safety and effectiveness through in vitro screening in the process of developing new drugs along with 2D products.

Nexel CEO Han Choong-seong said, “We decided to pursue an IPO to announce that we are a company with strong competitiveness based on our proprietary hiPSC technology and to secure a sustainable growth engine,” adding, “We plan to solidify our position as a global hiPSC specialist by diversifying our business portfolio through IPO.” he said.